TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: child cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Agitation level assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of Lactogenesis Stage II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume Attainment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline on executive function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FFI-foot function index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Subjects Who Were Seroprotected for HI Antibodies Against Each of the 4 Vaccine Influenza Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroconverted Subjects for HI Antibodies Against Each of the 4 Vaccine Influenza Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Psychopathological scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency or duration of challenging behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of metastatic cancer in regional lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in gut hormone levels measured in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Quality of life and resource data collection - Sf12
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life and resource data collection - EQ5D
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life and resource data collection - HADS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Innate Immunity Signatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prism cover test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Double product (DP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Triple product (TP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Muscular work
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MVTWA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reproducibility of MVTWA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Multiple System Atrophy-Quality of Life (MSA-QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to Discontinuation of Randomized Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Upper trapez and serratus anterior muscle strength ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Upper trapez and lower trapez muscle strength ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Seropositivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean geometric titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Ocular and Non-ocular Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Decision to Receive an ICD
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: trough blood levels of tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants with Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Complete Clearance of Actinic Keratoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Experience of taking antidepressants
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lesion status (active or healed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary PGE-MUM concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal Calprotectin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive and Negative Symptoms of Schizophrenia (PANSS) Total Score Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of rapid Opioid rotation
Endpoint domain: Adverse events/effects
Primary endpoint: A composite of cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clearance rate of kidney stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Plasma acylated ghrelin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma desacyl ghrelin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma butyrylcholinesterase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alleviation of stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Alleviation of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Enhancement of cognition ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of days lost due to unplanned cardiovascular hospitalisation
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of days lost due to death for any reason
Endpoint domain: Mortality/survival
Primary endpoint: Maternal and neonatal serum acetaminophen level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal breathing and body movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urgent TVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sentus QP Related Complication-free Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Acceptable Pacing Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients with a complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative expression of the NFKB1 gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relative expression of the Interleukin 6 (IL6) gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relative expression of the tumoral necrosis factor (TNF) gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relative expression of the Interleukin 1 B (IL1B) gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relative expression of the matrix metallopeptidase 9 (MMP) gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in PC20 values to methacholine bronchoprovocation challenges
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in PC15 values to hypertonic saline-induced bronchoprovocation challenges
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CISS MRI findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interictal Laryngoscopy findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Botox Injection outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: antiXa-levels (peak- and through-levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective neuropsychological tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence rates of hepatic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: incidence rates of pyrexia
Endpoint domain: Adverse events/effects
Primary endpoint: incidence rates of resistance
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Pain Interference Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decompensated heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Area under the Concentration Time Curve (AUC12) of Plan B (levonorgestrel)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: POAF occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacokinetic parameters of Huperzine A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in height/length z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: At-work performance deficits and productivity loss
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Absenteeism and productivity loss
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: mean change in frequency of headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durable Overall CSBM Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with MESTT Grade 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCins.0-12h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cins.max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUCGIR.0-last
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: GIRmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Clinical Global Impression - improvement scale (CGI-2) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Wound Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in visual analogue scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline In Ocular Itching Frequency Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Lipid Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hamilton Depression Rating Scale total score ≤ 8
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of urinary incontinence episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: COVID-19 associated immune disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: COVID-19 associated inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic of COVID disease composite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completeness of visualization of the small bowel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percent of sleep apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 11-point Numeric Pain Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-12 Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Foot Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Foot Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of Participants With Relapsed Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Body Dysmorphic Disorder Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of late gastro-intestinal toxicity ≥ grade 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Acute lung injury findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With One or More Major Access Site Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Total soluble circulation capacity for acetylcholine hydrolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Change in Area of Geographic Atrophy (GA) in Study Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Change in Area of Geographic Atrophy (GA) in Fellow Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Coping scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient acceptance of rapid HIV testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of the Glomerular Filtration Rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Complete remission rate of 24-hour urine protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Ventricular arrhythmia
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Confirmed Tumor Responses (CR or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of serious medical events
Endpoint domain: Adverse events/effects
Primary endpoint: Incremental area under curve for Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Average number of serrated lesions ≥ 10 mm detected per colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diabetes knowledge questionnaire (DKQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Summary of Diabetes Self-Care Activities-6 (SDSCA-6)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Diabetes Specific Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disability caused by low back pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Treatment-related Adverse Events Grade 3 or Higher
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Needing Corticosteroids
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 6-month smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume change on spatially registered images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gambling craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Plasma Level of Itraconazole at 1000 ng/mL or Higher
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of drug in system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat graft retention rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biodistribution of 68Ga-PSMA-11 compared to 18F-PSMA-1007
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline on Cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Severe preeclampsia incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: time-to-peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: enhancement ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: washout-time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in perceived fatigue severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in perceived cognitive impairment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in perceived depression or anxiety severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage reduction of the surface area of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Western Ontario Osteoarthritis of the Shoulder Score (WOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' or 'Almost Clear'
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response ≥ 75% Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of Peak Systolic Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disc Perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in expression levels of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of oral irinotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gait mechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Composite of Deaths / MIs / Invasive Coronary Angiography Without Obstructive Disease
Endpoint domain: Mortality/survival
Primary endpoint: Macrosomia incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression Free Survival (PFS) by RECIST 1.1
Endpoint domain: Mortality/survival
Primary endpoint: Percent of samples contaminated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of cells that are viable following post thaw analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indications for capsule endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of virological remission (HBV DNA <20 IU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted odds ratio of peri-operative clinical risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Pyrogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Sex Risk Behavior at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Risk behavior
Primary endpoint: Change from Baseline in HIV Testing Rates at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Health behavior
Primary endpoint: Number of Network Members Recruited for HIV Testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent Change in Muscle Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: HbA1c Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: secondary caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: BOLD-signal change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Magnitude of exercise time improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of peri-implant bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding Self-Efficacy Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rates of protocol violation
Endpoint domain: Adverse events/effects
Primary endpoint: delays
Endpoint domain: Resource use
Primary endpoint: Detection of optic neuropathies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Malnutrition (based on SGA assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Malnutrition inflammation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endotracheal leak detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical outcome (cure, failure, not evaluable)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Who Complete the Regimen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Functional Walking Test (FWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New acute coronary syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Prolonged Air Leaks
Endpoint domain: Adverse events/effects